Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 14, 2016, Pages 1923-1936

  Ribeiro de Souza, Andrea ^a   Reig, Maria ^a   Bruix, Jordi ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Clinical trial; hepatocelullar carcinoma; molecular therapy; radiological progression; regorafenib; sorafenib

Indexed keywords

CABOZANTINIB; LENVATINIB; NIVOLUMAB; OCTREOTIDE; PEMBROLIZUMAB; RAMUCIRUMAB; REGORAFENIB; SCATTER FACTOR RECEPTOR; SORAFENIB; TICILIMUMAB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PATIENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOEMBOLIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; LIVER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES;

EID: 84988432430     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1225722     Document Type: Review

References (102)

1. J.Ferlay, I.Soerjomataram, R.Dikshit, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
2. S.Mittal, H.B.El-Serag Epidemiology of hepatocellular carcinoma:consider the population. J Clin Gastroenterol. 2013;47(Suppl(00)):SS2–SS6.
3. A.P.Venook, C.Papandreou, J.Furuse, et al. The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective. Oncologist. 2010;15(suppl 4):5–13.
4. N.Howlader, A.M.Noone, M.Krapcho, et al. SEER cancer statistics review, 1975-2013. National Cancer Institute; 2016 [cited Aug 2016]. SEER web site. Available from: http://seer.cancer.gov/csr/1975_2013/
5. A.Forner, M.E.Reig, C.Rodriguez De Lope, et al. Current strategy for staging and treatment:the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.
6. J.Bruix, M.Sherman, J.M.Llovet, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Eur Assoc Study Liver. 2001;35:421–430.
7. J.Bruix, M.Reig, M.Sherman. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853.•• Current BCLC algorithm and updated review of the scientific evidence to diagnose and treat HCC
8. EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.•• Clinical practice guidelines of hepatocellular carcinoma of the European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer.
9. U.Cillo, M.Bassanello, A.Vitale, et al. The critical issue of hepatocellular carcinoma prognostic classification:which is the best tool available ? J Hepatol. 2004;40(1):124–131.
10. A.Grieco, M.Pompili, G.Caminiti, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54(3):411–418.
11. J.A.Marrero, R.J.Fontana, A.Barrat, et al. Prognosis of hepatocellular carcinoma:comparison of 7 staging systems in an American cohort. Hepatology. 2005;41(4):707–716.
12. G.Cabibbo, M.Enea, M.Attanasio, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274–1283.• Meta-analysis that evaluated the 1-year and 2-year survival rates of untreated HCC patients enrolled in RCTs of palliative treatments and identified prognostic factors.
13. P.Ferenci, M.Fried, D.Labrecque, et al. Hepatocellular carcinoma (HCC):a global perspective. J Clin Gastroenterol. 2010;44(4):239–245.•• Clinical practice guidelines of Hepatocellular Carcinoma of the World Gastroenterology Organisation.
14. C.Verslype, O.Rosmorduc, P.Rougier. Hepatocellular carcinoma:ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii41–vii48.•• Clinical practice guidelines of Hepatocellular Carcinoma of the European Society for Medical Oncology and European Society of Digestive Oncology
15. J.M.Llovet, J.Bustamante, A.Castells, et al. Natural history of untreated nonlsurgical hepatocellular carcinoma:rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–67.
16. S.Tremosini, M.Reig, C.R.De Lope, et al. Treatment of early hepatocellular carcinoma:towards personalized therapy. Dig Liver Dis. 2010;42:S242–S248.
17. J.M.Llovet, J.Fuster, J.Bruix. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:resection versus transplantation. Hepatology. 1999;30:1434–1440.
18. A.Berzigotti, M.Reig, J.G.Abraldes, et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis:a systematic review and meta-analysis. Hepatology. 2015;61(2):526–536.
19. A.Forner, M.Gilabert, J.Bruix, et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525–535.• Review of the scientific evidence for the management and prognosis of intermediate stage HCC (BCLC-B)
20. M.Burrel, M.Reig, A.Forner, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330–1335.
21. J.Bruix, P.Merle, A.Granito, et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib:results of the international, randomized phase 3 RESORCE trial. Ann Oncol. 2016;27(suppl2; abstract LBA 03):ii 1–ii 3.•• Phase 3 double-blind placebo-controlled clinical trial testing regorafenib in patients with HCC who presented progression under sorafenib. Patients in the regorafenib group had a 38% reduction in the risk of death comparing with placebo.
22. J.M.Llovet, S.Ricci, V.Mazzaferro, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.•• The pivotal phase 3 double-blind placebo-controlled clinical trial (SHARP) that has demonstrated that sorafenib significantly increases the survival of patients with HCC with an adequate safety profile.
23. A.L.Cheng, Y.K.Kang, Z.Chen, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.•• The Asian-Pacific phase 3 clinical trial that has shown that sorafenib improves survival in the Asiatic population with advanced HCC.
24. J.Bruix, M.Sherman. Management of hepatocellular carcinoma:an update. Hepatology. 2011;53(3):1020–1022.•• Updated guidelines of the American Association for the Study of Liver Disease (AASLD)
25. J.Bruix, M.Reig, J.Rimola, et al. Clinical decision making and research in hepatocellular carcinoma:pivotal role of imaging techniques. Hepatology. 2011;54:2238–2244.
26. M.Reig, A.Darnell, A.Forner, et al. Systemic therapy for hepatocellular carcinoma:the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis. 2014;34(4):444–455.•• Review of the BCLC management of HCC and presentation of the different proposals to assess tumor response and tumor progression in HCC patients.
27. S.M.Wilhelm, C.Carter, L.Tang, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109.
28. D.Strumberg, H.Richly, R.A.Hilger, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2004;23(5):965–972.
29. M.F.Sprinzl, A.Puschnik, A.M.Schlitter, et al. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J Hepatol. 2015;62(4):863–870.
30. M.F.Sprinzl, F.Reisinger, A.Puschnik, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology. 2013;57(6):2358–2368.
31. G.K.Abou-Alfa, L.Schwartz, S.Ricci, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–4300.
32. F.Duffaud, P.Therasse. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 2000;87(3):881–886.
33. J.Bruix, J.-L.Raoul, M.Sherman, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma:subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–829.
34. M.Iavarone, G.Cabibbo, F.Piscaglia, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma:a prospective multicenter study in Italy. Hepatology. 2011;54(6):2055–2063.
35. R.Lencioni, M.Kudo, S.-L.Ye, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib):second interim analysis. Int J Clin Pract. 2014;68(5):609–617.
36. M.Reig, J.Rimola, F.Torres, et al. Postprogression survival of patients with advanced hepatocellular carcinoma:rationale for second-line trial design. Hepatology. 2013;58:2023–2031.•• Prospective study that has shown that tumor progression is a surrogate of survival but its impact varies according to progression pattern. Postprogression survival is influenced by progression pattern and this is key in prognostic prediction and second-line trial design and analysis.
37. H.Huynh, T.T.T.Nguyen, K.-H.P.Chow, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma:its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.
38. M.Caraglia, G.Giuberti, M.Marra, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2:e150.
39. H.Yoshiji, S.Kuriyama, J.Yoshii, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology. 2004;39(6):1517–1524.
40. M.Reig, F.Torres, C.Rodriguez-Lope, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61(2):318–324.
41. S.M.Wilhelm, J.Dumas, L.Adnane, et al. Regorafenib (BAY 73-4506):a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.• Preclinical study that has shown that regorafenib is a well tolerated, orally active multikinase inhibitor with a distinct target profile that might have therapeutic benefit in human malignancies.
42. K.Mross, A.Frost, S.Steinbild, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–2667.
43. J.Bruix, W.-Y.Tak, A.Gasbarrini, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49(16):3412–3419.• Phase 2 clinical trial that has shown that regorafenib has acceptable tolerability and evidence of antitumour activity in patients with intermediate or advanced HCC that progress following first-line sorafenib.
44. R.S.Finn, R.T.P.Poon, T.Yau, et al. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol. 2013;59(6):1271–1277.
45. D.Koeberle, J.-F.Dufour, G.Demeter, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC):a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016;27(5):856–861.
46. P.A.Philip, M.R.Mahoney, C.Allmer, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–6663.
47. A.X.Zhu, O.Rosmorduc, T.R.J.Evans, et al. SEARCH:a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–566.
48. A.-L.Cheng, Y.-K.Kang, D.-Y.Lin, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer:results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–4075.
49. P.J.Johnson, S.Qin, J.W.Park, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma:results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–3524.
50. C.Cainap, S.Qin, W.-T.Huang, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–179.
51. J.M.Llovet, T.Decaens, J.L.Raoul, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509–3516.
52. A.X.Zhu, M.Kudo, E.Assenat, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57–67.
53. A.X.Zhu, J.O.Park, B.-Y.Ryoo, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH):a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul;16(7):859–870.
54. S.Qin, Y.Bai, H.Y.Lim, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–3508.
55. G.K.Abou-Alfa, S.Qin, B.Y.Ryoo, et al. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2016;34(suppl; abstr 4017). Available from:http://meetinglibrary.asco.org/content/168041-176.
56. M.Kudo, K.Ueshima, O.Yokosuka, et al. Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. J Hepatol. 2016;64:S183–S212.
57. G.K.Abou-Alfa, D.Niedzwieski, J.J.Knox, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC):CALGB 80802 (Alliance). J Clin Oncol. 2016;34(suppl; abstract 4078). Available from:http://meetinglibrary.asco.org/content/159480-173.
58. F.Izzo, P.Marra, G.Beneduce, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma:results from phase I/II studies. J Clin Oncol. 2004;22(10):1815–1822.
59. E.S.Glazer, M.Piccirillo, V.Albino, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol. 2010;28(13):2220–2226.
60. T.-S.Yang, S.-N.Lu, Y.Chao, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer. 2010;103(7):954–960.
61. M.Ikeda, T.Okusaka, S.Mitsunaga, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2016 Mar 15;22(6):1385–1394.
62. R.S.Finn, A.L.Cheng, K.Ikeda, et al. A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. J Clin Oncol. 2014;(suppl; abstr TPS4153). Available from:http://meetinglibrary.asco.org/content/132120-144.
63. B.Sangro, I.Melero, T.C.Yau, et al. Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC):interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study. J Clin Oncol. 2016;34(suppl;abstr 4078). Available from:http://meetinglibrary.asco.org/content/167143-176.
64. A.X.Zhu, R.S.Finn, M.Mulcahy, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19(23):6614–6623.
65. C.Verslype, A.L.Cohn, R.K.Kelley, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma:results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(suppl; abstr 4007). Available from:http://meetinglibrary.asco.org/content/95343-114.
66. A.Santoro, M.Simonelli, C.Rodriguez-Lope, et al. A phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinomaand cirrhosis. Br J Cancer. 2013;108(1):21–24.
67. A.Santoro, L.Rimassa, I.Borbath, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma:a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63.
68. S.Qin. Apatinib in Chinese patients with advanced hepatocellular carcinoma:a phase II randomized, open-label trial. J Clin Oncol. 2014;32:sup:abstr4019.
69. L.Boix, J.L.Rosa, F.Ventura, et al. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology. 1994;19(1):88–91.
70. K.C.Bible, M.Ryder. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016;13(7):403–416.
71. J.L.Spratlin, R.B.Cohen, M.Eadens, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780–787.
72. J.Prieto, I.Melero, B.Sangro. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681–700.•• Review of the data on HCC immunogenicity, the mechanisms for HCC immune subversion, and the different immunotherapies that have been tested to treat HCC.
73. J.J.Harding, I.El Dika, G.K.Abou-Alfa. Immunotherapy in hepatocellular carcinoma:primed to make a difference? Cancer. 2015;122:367–377.
74. M.F.Sprinzl, P.R.Galle. Immune control in hepatocellular carcinoma development and progression:role of stromal cells. Semin Liver Dis. 2014;34(4):376–388.
75. F.S.Hodi, S.J.O’Day, D.F.McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
76. S.L.Topalian, F.S.Hodi, J.R.Brahmer, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
77. B.Sangro, C.Gomez-Martin, M.De La Mata, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88.
78. J.Hamanishi, M.Mandai, N.Matsumura, et al. PD-1/PD-L1 blockade in cancer treatment:perspectives and issues. Int J Clin Oncol. 2016;21(3):462–473.
79. A.B.El-Khoueiry, I.Melero, T.S.Crocenzi, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC):CA209-040. J Clin Oncol. 2015;33:LBA101.
80. E.D.Deeks. Pembrolizumab:a review in advanced melanoma. Drugs. 2016;76(3):375–386.
81. J.Altomonte, O.Ebert. Sorting out Pandora’s box:discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma. Front Oncol. 2014;4:85.
82. J.Heo, T.Reid, L.Ruo, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329–336.
83. B.Sangro, M.Iñarrairaegui, J.I.Bilbao. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464–473.
84. R.Salem, V.Mazzaferro, S.B.Yttrium. 90 radioembolization for the treatment of hepatocellular carcinoma:biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58(6):2188–2197.
85. P.Hilgard, M.Hamami, E.Fouly, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma:European experience on safety and long-term survival. Hepatology. 2010;52:1741–1749.
86. B.Sangro, L.Carpanese, R.Cianni, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages:a European evaluation. Hepatology. 2011;54(3):868–878.
87. R.Salem, R.J.Lewandowski, M.F.Mulcahy, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.
88. M.A.De La Torre, J.Buades-Mateu, P.A.De La Rosa, et al. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int. 2016;36(8):1206–1212.
89. J.Edeline, L.Crouzet, B.Campillo-Gimenez, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2016;43(4):635–643.
90. A.Gramenzi, R.Golfieri, C.Mosconi, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma:a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036–1047.
91. O.M.Abdel-Rahman, Z.Elsayed. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2016;2:CD011313.
92. V.Trochon-Joseph, C.Lemarchand, V.Hayes, et al. Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines. Cancer Res 2016;76(14 Suppl):Abstract no. 2143.
93. P.S.Del, L.Montella, M.Caraglia, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma:multicenter phase II So.LAR. study. Cancer Chemother Pharmacol. 2010;66(5):837–844.
94. G.Becker, H.-P.Allgaier, M.Olschewski, et al.; HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC:a randomized controlled double-blind study. Hepatology. 2007;45(1):9–15.
95. C.G.Moertel, J.A.Hanley. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976;38:388–394.
96. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva:World Health Organization; 1979.
97. E.A.Eisenhauer, P.Therasse, J.Bogaerts, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
98. R.Lencioni, J.Llovet. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):52–60.
99. F.S.Hodi, W.-J.Hwu, R.Kefford, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–1517.
100. J.D.Wolchok, A.Hoos, S.O’Day, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420.
101. J.M.Llovet, A.Villanueva, A.Lachenmayer, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408–424.
102. A.A.Alizadeh, V.Aranda, A.Bardelli, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21(8):846–853.